US › Healthcare

Cardiol Therapeutics Inc Class A (CRDL)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.10-4.35%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.6M

EPS

$-0.04

EPS estimate

$-0.09

EPS came in at -0.04 against a street estimate of -0.09 — a beat of 55.6%.

Key statistics

Market cap

$149.5M

Forward P/E

0.0

P/B

12.49

Book value

$0.15

EPS (TTM)

$-0.25

52-week high

$2.34

52-week low

$0.88

50-day MA

$1.75

200-day MA

$1.29

Beta

0.72

Analyst view

Analysts rate Cardiol Therapeutics Inc Class A a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $8.37.

Shareholding

Insiders

2.27%

Institutions

26.40%

Largest institutional holders

Fund	Stake
Mmcap International Inc. Spc	12.84%
Tejara Capital Ltd	4.21%
Ikarian Capital, LLC	2.74%
BOOTHBAY FUND MANAGEMENT, LLC	0.80%
Citadel Advisors Llc	0.66%
Renaissance Technologies Corp	0.64%
Two Sigma Investments LLC	0.61%
INTEGRITY ALLIANCE, LLC.	0.32%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cardiol Therapeutics Inc Class A — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.